Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's MHLW Approves Request For Needed Drugs That Can Bypass Clinical Trials

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's Ministry of Health, Labor and Welfare is urging manufacturers to develop drugs for Japan that are still unapproved or unapproved for additional indications already approved in the West. Some drugs considered highly medically necessary may qualify for approval via a known-art application without conducting new clinical trials in Japan. The move is part of the ministry's ongoing efforts to reduce the country's much talked about drug lag
Advertisement

Related Content

Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?
Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?
PMDA Cuts Review Lag With West In Half, But Application Lag Shows No Relief For Drug Launches In Japan
Tokyo Aims To Speed Up Drug Approvals, Catch Up With U.S., Says Japanese Health Ministry Official
Tokyo Aims To Speed Up Drug Approvals, Catch Up With U.S., Says Japanese Health Ministry Official
Advertisement
UsernamePublicRestriction

Register

SC077987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel